Discover
HOWL
Werewolf Therapeutics, Inc.
0.35
2 x 0.25
11 x 0.37
bid
ask
-
0.01
1.92%
7 @ 04:00 PM
0.36 +0.00 (0.82%)
| Ytd | -44.32% | |
| 1y | -66.38% |
0.35
day range
0.37
0.27
52 week range
2.38
| Open | 0.36 | Prev Close | 0.36 | Low | 0.35 | High | 0.37 | Mkt Cap | 17.15M |
| Vol | 1.36M | Avg Vol | 607.84K | EPS | -1.21 | P/E | N/A | Forward P/E | -0.86 |
| Beta | 0.41 | Short Ratio | 2.09 | Inst. Own | 72.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 0.52 | 200-d Avg | 0.89 | 1yr Est | 12.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.41 | -0.38 | 0.03 | 7.32% |
| 2024-08-08 | 2024-06 | -0.38 | -0.43 | -0.05 | -13.16% |
| 2024-08-08 | 2024-06 | -0.38 | N/A | N/A | N/A |
| 2024-05-03 | 2024-03 | -0.35 | -0.39 | -0.04 | -11.43% |
| 2024-05-03 | 2024-03 | -0.35 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.43 | -0.33 | 0.1 | 23.26% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-26 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-06-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-04 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-06-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-01-05 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 6.14M | 9.65M | 13.79% |
| 2024-09-29 | MPM Asset Management, LLC | 4.28M | 6.73M | 9.61% |
| 2024-09-29 | Pfm Health Sciences, Lp | 3.40M | 5.34M | 7.63% |
| 2024-09-29 | MPM BioImpact Capital LLC | 2.39M | 3.75M | 5.36% |
| 2024-09-29 | Bank of America Corporation | 2.15M | 3.38M | 4.83% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 2.00M | 3.14M | 4.49% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 800.28K | 1.26M | 1.80% |
| 2024-10-30 | iShares Russell 2000 ETF | 676.89K | 1.06M | 1.52% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 392.16K | 615.69K | 0.88% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 310.65K | 487.73K | 0.70% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 211.77K | 332.48K | 0.48% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 171.31K | 268.95K | 0.38% |